Real-life effectiveness of dupilumab in patients with mild to moderate bronchial asthma comorbid with CRSwNP

Authors:

Abstract
(Background) Dupilumab, an anti-IL-4α receptor antibody, is a new treatment for severe or refractory asthma, but real-world evidence is lacking for the efficacy of dupilumab in patients with mild to moderate bronchial asthma.(Methods) We retrospectively evaluated the effect of dupilumab in 62 patients received with dupilumab for eosinophilic sinusitis comorbid with asthma at a single center in Japan. Type 2 inflammatory markers, ACT, respiratory function tests, and forced oscillation technique (FOT) were analyzed before, three months after, and one year after dupilumab administration, mainly in patients with mild to moderate asthma.(Results) FEV1, %FEV1, %FVC, treatment step for asthma and ACT improved significantly after three months of dupilumab treatment. FeNO was markedly decreased, whereas IgE and eosinophil counts showed no significant changes. Pre and post-treatment respiratory resistance (Rrs) and respiratory reactance (Xrs) correlated significantly with FEV1. Improvement in %FEV1 was associated with higher FeNO and higher serum IgE before dupilumab treatment.(Conclusion) Dupilumab treatment for sinusitis may benefit respiratory function, asthma symptoms, and asthma treatment reduction, even if the associated bronchial asthma is not severe.